A unified framework for pre-screening and screening tools in oncology clinical trials
Clinical trial enrollment in oncology remains limited by increasingly complex eligibility criteria, biomarker stratification, and fragmented clinical data, contributing to prolonged recruitment timelines and low participation rates. This review examines contemporary pre-screening and screening approaches, spanning manual workflows, health-system-embedded digital tools, and emerging artificial intelligence-enabled methods. We assess the relative strengths and limitations of large language model-based strategies, including retrieval-augmented and domain-adapted approaches, in addressing scalability, accuracy, and equity challenges. Hybrid frameworks that integrate automated screening with clinician oversight appear most effective in improving trial matching efficiency, representativeness, and timely access to investigational therapies across diverse oncology populations.
Authors
- Denis Horgan (ORCID: https://orcid.org/0000-0003-4392-4505)
- Frédérique Penault Lorca
- V. Subbiah
- Arturo Loaiza-Bonilla
- Christer Svedman
- Paul Hofman
- Daniel Schneider
- Hadi Mohamad Abu Rahsheed
- Joe Paulson
- Stan Kachnowsk
- Umberto Malapelle
Institutions
- St. Luke's University Health Network (US)
- Qatar Airways (Qatar) (QA)
- Johnson & Johnson (United States) (US)
- Exelixis (United States) (US)
- Université Clermont Auvergne (FR)
- Sam Higginbottom Institute of Agriculture (IN)
- Yale University (US)
- Emergency University (US)
- Sarah Cannon (US)
- Centre Jean Perrin (FR)
- Hôpital Pasteur (FR)
- Massey University (NZ)
- University of Naples Federico II (IT)
- Columbia University (US)
Publication Details
- Journal
- npj Precision Oncology
- Published
- 2026-01-30
- DOI
- https://doi.org/10.1038/s41698-026-01306-3
- Primary Topic
- Cancer Genomics and Diagnostics
- Type
- article
- Field-Weighted Citation Impact
- 0.00